We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$142M
1-Year Est. Return
783.79%
This Fund
S&P 500
This Quarter
Est. Return
+2.49%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$280M
AUM Growth
-$281M
(-50%)
Cap. Flow
-$284M
Cap. Flow
% of AUM
-101.42%
Top 10 Holdings %
Top 10 Hldgs %
74.06%
Holding
63
New
4
Increased
2
Reduced
14
Closed
32
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KALV
KalVista Pharmaceuticals
KALV
|
+$1.74M |
| 2 |
ECYT
Endocyte, Inc. Common Stock
ECYT
|
+$1.58M |
| 3 |
Xenon Pharmaceuticals
XENE
|
+$377K |
| 4 |
AMRN
Amarin Corp
AMRN
|
+$268K |
| 5 |
Coherus Oncology
CHRS
|
+$151K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$63.8M |
| 2 |
argenx
ARGX
|
+$30.9M |
| 3 |
Iovance Biotherapeutics
IOVA
|
+$25.6M |
| 4 |
Veracyte
VCYT
|
+$17.3M |
| 5 |
Ascendis Pharma A/S
ASND
|
+$16.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 72.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMMU
1
DELISTED
Immunomedics Inc
IMMU
| $42.8M | 15.27% |
2,055,500
-2,694,500
| -57% | -$63.8M |
|
2
Assembly Biosciences
ASMB
$503M
| $34.5M | 12.32% |
77,500
-19,333
| -20% | -$9.06M |
|
|
3
Iovance Biotherapeutics
IOVA
$1.93B
| $25M | 8.92% |
2,222,701
-1,802,299
| -45% | -$25.6M |
|
|
KDMN
4
DELISTED
Kadmon Holdings, Inc.
KDMN
| $24.7M | 8.81% |
7,395,000
-1,665,014
| -18% | -$5.91M |
|
|
CEMI
5
DELISTED
Chembio diagnostics, Inc.
CEMI
| $21.3M | 7.61% |
2,030,533
| – | – |
|
6
Arrowhead Research
ARWR
$12.1B
| $14.9M | 5.3% |
775,000
-255,330
| -25% | -$4.19M |
|
7
IRIDEX
IRIX
$14.4M
| $12.4M | 4.41% |
1,947,500
-52,500
| -3% | -$390K |
|
|
CASM
8
DELISTED
CAS Medical Systems, Inc.
CASM
| $12M | 4.28% |
5,263,508
| – | – |
|
|
9
Veracyte
VCYT
$3.58B
| $10.4M | 3.72% |
1,092,500
-1,567,710
| -59% | -$17.3M |
|
10
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
| $9.59M | 3.42% |
100,000
| – | – |
|
11
PUT
Regeneron Pharmaceuticals
REGN
$78.2B
| $8.08M | 2.88% |
20,000
| – | – |
|
|
12
argenx
ARGX
$52B
| $7.96M | 2.84% |
105,000
-348,233
| -77% | -$30.9M |
|
13
Madrigal Pharmaceuticals
MDGL
$11.1B
| $7.07M | 2.52% |
33,000
-1,803
| -5% | -$452K |
|
|
14
Xenon Pharmaceuticals
XENE
$6.02B
| $6.37M | 2.27% |
482,500
+32,500
| +7% | +$377K |
|
|
15
Coherus Oncology
CHRS
$222M
| $5.83M | 2.08% |
353,500
+8,500
| +2% | +$151K |
|
|
16
CALL
Assembly Biosciences
ASMB
$503M
| $5.48M | 1.95% |
12,292
| – | – |
|
|
17
Ascendis Pharma A/S
ASND
$16B
| $5.07M | 1.81% |
71,500
-239,611
| -77% | -$16.5M |
|
|
BHVN
18
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $4.97M | 1.77% |
132,500
-27,500
| -17% | -$1.01M |
|
|
19
CALL
Arrowhead Research
ARWR
$12.1B
| $3.83M | 1.37% |
200,000
| – | – |
|
|
ACER
20
DELISTED
Acer Therapeutics Inc
ACER
| $3.37M | 1.2% |
109,270
| – | – |
|
|
VRAY
21
DELISTED
ViewRay, Inc.
VRAY
| $2.92M | 1.04% |
311,500
-1,183,500
| -79% | -$11.6M |
|
|
KALV
22
DELISTED
KalVista Pharmaceuticals
KALV
| $2.85M | 1.02% |
+128,844
| New | +$1.74M |
|
23
Dianthus Therapeutics
DNTH
$5.8B
| $2.04M | 0.73% |
10,625
| – | – |
|
|
BHVN
24
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $2.02M | 0.72% |
53,800
| – | – |
|
|
ECYT
25
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $1.63M | 0.58% |
+92,000
| New | +$1.58M |
|
Similar funds
EC
YEPX
SR
IA
MAM
HA
VVM
KCAM
Acuta Capital Partners's Q3 2018 Portfolio in Review
As of Q3 2018, Acuta Capital Partners held 63 positions worth $280M, down 50% from $562M the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Acuta Capital Partners withdrew a net $284M in Q3 2018, closing 32 positions and reducing 14 holdings. Its most notable exit was Indaptus Therapeutics, an estimated $13M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 68% a quarter earlier.
Against the trend, Acuta Capital Partners opened a new position in KalVista Pharmaceuticals worth $2.85M.
- Acuta Capital Partners's largest Q3 2018 buy was KalVista Pharmaceuticals: 128,844 shares worth $2.85M.
- Acuta Capital Partners added most to Xenon Pharmaceuticals in Q3 2018, an estimated $377K increase.
- Acuta Capital Partners's biggest Q3 2018 reduction was Immunomedics Inc, cutting an estimated $63.8M.
- Acuta Capital Partners fully exited Indaptus Therapeutics in Q3 2018, selling an estimated $13M.
- Acuta Capital Partners's ten largest holdings make up 74% of its $280M portfolio in Q3 2018.
- Acuta Capital Partners opened 4 new positions and closed 32 in Q3 2018.
- Acuta Capital Partners's portfolio value fell 50% quarter-over-quarter to $280M.
Based on Acuta Capital Partners's 13F filing for Q3 2018, filed 7 Nov 2018.